For this pilot study, we examined three different therapies known to either stimulate or preserve insulin secretion in people with diabetes and residual C-peptide: namely, liraglutide, a GLP-1R agonist; verapamil, a calcium channel blocker; and golimumab, a TNF-α blocking agent. Here, TNF is linked to diabetes mellitus.